Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

Study Identifier
MA-COM004
CT.gov Identifier
NCT01151904
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Glaucoma - Other
    • Study Drug
  • brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution
  • latanoprost
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient has been administering latanoprost eye drops in affected eye(s) for at least 12 weeks prior to study * Patient must have at least partially responded to latanoprost and requiring further IOP lowering eye drops * Diagnosis of chronic angle-closure glaucoma * Patients using COMBIGAN® in the past must not have been discontinued due to adverse events or lack of efficacy.
    Exclusion Criteria:
    * Known allergy or hypersensitivity to COMBIGAN® * Corneal abnormalities that would preclude accurate IOP readings * Any other active ocular disease other than glaucoma or ocular hypertension * Ocular surgery within the past 3 months.

    Protocol Summary

    This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

    Study Locations

    Location
    Status
    Location
    Bangkok, Thailand
    Status
    Not applicable